Anthera Pharmaceuticals, Inc.
ANTH · OTC
12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.02 | 0.16 | 0.05 |
| FCF Yield | -200.56% | -185.39% | -18.74% | -74.41% |
| EV / EBITDA | -0.61 | -0.10 | -3.39 | -1.13 |
| Quality | ||||
| ROIC | 3,509.83% | -429.67% | -88.09% | 1,258.69% |
| Gross Margin | 0.00% | 68.10% | 99.03% | 0.00% |
| Cash Conversion Ratio | 1.37 | 0.88 | 0.88 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | – | – |
| Free Cash Flow Growth | 25.73% | -60.34% | -21.04% | 19.81% |
| Safety | ||||
| Net Debt / EBITDA | 0.08 | 0.37 | 1.34 | 0.09 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -27.13 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,379.64 | -37,738.21 | -62,164.03 | -37,303.91 |